PureTech’s Andrew Miller and Ketki Karanam Named to MedTech Boston’s Top 40 Under 40 Healthcare Innovators List

Winners chosen for commitment to changing healthcare system in disruptive ways

BOSTON--()--PureTech Health plc (“PureTech”, LSE: PRTC), a cross-disciplinary healthcare company tackling fundamental healthcare needs, is proud to announce that Andrew Miller, Ph.D., Vice President at PureTech and Co-Founder of both Tal Medical and Karuna Pharmaceuticals, and Ketki Karanam, Ph.D., Senior Associate at PureTech and Co-Founder and Head of Science at The Sync Project, were named to MedTech Boston’s 40 Under 40 Healthcare Innovators list. The winners were chosen based on their commitment to changing the healthcare system in disruptive ways and will be honored at an awards ceremony in June.

“PureTech is so proud of Andrew and Ketki for earning this distinction from MedTech Boston,” said PureTech Co-Founder and Chief Executive Officer, Daphne Zohar. “They are both dedicated champions of our mission to improve the lives of patients, and we are thrilled they have been recognized for their efforts. Congratulations to Andrew, Ketki and the rest of the 40 Under 40 Healthcare Innovators winners.”

Andrew Miller – Dr. Miller is a Vice President at PureTech and a co-founder of Tal Medical and Karuna Pharmaceuticals. He currently serves as the Chief Operating Officer for Tal Medical, and he is a co-inventor of Karuna’s technology platform, where he serves as a Board Member. Dr. Miller also serves on the Board of Directors for Entrega. Dr. Miller completed his doctoral work focusing on polymeric biomaterials at the Massachusetts Institute of Technology (MIT). In graduate school, he was awarded the National Defense Science and Engineering Graduate Fellowship and completed course work at the MIT Sloan School of Management. Dr. Miller received his bachelor of science in chemical engineering from the University of Illinois at Urbana-Champaign and his Ph.D. in chemical engineering from MIT.

Ketki Karanam – Dr. Karanam is a Senior Associate at PureTech, and is a Co-Founder and Head of Science at The Sync Project. She completed her doctoral work at Harvard University in the Department of Systems Biology, focusing on DNA repair in cancer cells. While a graduate student, Dr. Karanam served as a Fellow with the Harvard Office of Technology Development, where she worked on translating emerging life science technologies into commercial healthcare products. Dr. Karanam received her bachelor of science in microbiology from Pune University, India, and her master’s degree in biological sciences from the Indian Institute of Science, during which time she held the national Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) and Rajiv Gandhi Science Talent fellowships. She received her Ph.D. in systems biology from Harvard.

Tal Medical is a clinical stage neuroscience business, developing a non-invasive, rapid-acting therapy for depression.

Karuna Pharmaceuticals is developing clinical stage therapies for the treatment of schizophrenia.

Entrega is developing a platform technology for the oral delivery of biologics, vaccines and other forms of medication that are otherwise not efficient in reaching the bloodstream when taken orally.

The Sync Project is creating music as personalized medicine and is positioned to become the first algorithmic music therapeutics company.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company developing innovative products that could improve the lives of billions of patients. PureTech is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastro-intestinal and immune systems, and the interactions and signaling between them. PureTech has a pipeline of more than 30 programs and has approximately 20 clinical studies across its pipeline, targeting multi-billion dollar market opportunities. PureTech’s advanced programs include five with human proof-of-concept and multiple with pivotal or registration study readouts in the next two years. PureTech's leading team and board, along with an advisory network of more than 60 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. With healthcare undergoing major transformation, PureTech believes it is well positioned to develop and launch medicines for the 21st century. For more information, visit www.puretechhealth.com and connect with us on Twitter.

Contacts

PureTech Health
Allison Mead, 617-651-3156
Associate Director, Communications and Investor Relations
amead@puretechhealth.com

Release Summary

PureTech’s Andrew Miller and Ketki Karanam Named to MedTech Boston’s Top 40 Under 40 Healthcare Innovators List

Contacts

PureTech Health
Allison Mead, 617-651-3156
Associate Director, Communications and Investor Relations
amead@puretechhealth.com